Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases

Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted antibodies SOUTH SAN FRANCISCO, CA, Sept. 10, 2026 – Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of